EirGenix
台康生技股份有限公司
EirGenix is a Taiwan TWSE-listed biotechnology company; its most advanced asset is EG1206A (Marketing authorization application submitted, HER2-positive breast cancer), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| EG1206A | HER2 | Marketing authorization application submitted | HER2-positive breast cancer | European Union | 2026-10-07 | Company disclosure |
| EG12014 | — | — | — | — | 2026-07-12 | Company disclosure |
Key events
- Business update (company filing)
- Business update (company filing)
- Business update (company filing)
Related Drugnews articles
No related articles in this language.